RxDoctor Payments Data

Eric Kleeman, MD

Family Medicine · Tell City, INNPI 1063517308

Payments from drug & device makers

$11,715in general payments, 2019–2025

Across 851 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • GSK$903
  • Novo Nordisk$860
  • Lilly USA, LLC$730
  • Pfizer$630
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$11,49398%
  • Education$2222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,715 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$182,922
Medicare patients
546
Services billed
3,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide134$160,294
EliquisApixaban142$105,879
OzempicSemaglutide72$84,684
FarxigaDapagliflozin Propanediol48$63,939
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$51,945
CoregCarvedilol36$37,489
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$35,511
XareltoRivaroxaban36$31,562
JardianceEmpagliflozin41$25,916
RexultiBrexpiprazole20$24,699
JanuviaSitagliptin Phosphate23$18,050
MyrbetriqMirabegron37$16,866
TrulicityDulaglutide14$16,255
Tresiba Flextouch U-100Insulin Degludec29$15,286
LinzessLinaclotide20$14,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$730$176,549148 claims
PfizerEliquis, Paxlovid$630$110,165160 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,483$108,683109 claims
Novo NordiskOzempic$860$84,68472 claims
GSKTrelegy Ellipta, Breo Ellipta$903$62,24573 claims
Boehringer IngelheimJardiance, Spiriva Respimat$278$39,54753 claims
Johnson & JohnsonXarelto$413$31,56236 claims
MerckJanuvia, Belsomra$459$29,15541 claims
Otsuka America Pharmaceutical, Inc.Rexulti$51$24,69920 claims
AbbVieLinzess, Synthroid$1,513$19,84463 claims
NovartisEntresto$474$8,51212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Tell City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →